What is a stock summary page? Click here for an overview.
Business Description
Celldex Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US15117B2025
Compare
Compare
Traded in other countries / regions
CLDX.USATCE2.Germany Index Membership
Russell 2000Russell 3000 IPO Date
1990-03-26Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 190.21 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 12.94 | |||||
| Beneish M-Score | -3.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.3 | |||||
| 3-Year EBITDA Growth Rate | -24.6 | |||||
| 3-Year EPS without NRI Growth Rate | -23.6 | |||||
| 3-Year FCF Growth Rate | -19.6 | |||||
| 3-Year Book Growth Rate | 7.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -8.59 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.3 | |||||
| 9-Day RSI | 31.05 | |||||
| 14-Day RSI | 33.94 | |||||
| 3-1 Month Momentum % | -27.83 | |||||
| 6-1 Month Momentum % | -37.26 | |||||
| 12-1 Month Momentum % | -52.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.91 | |||||
| Quick Ratio | 18.91 | |||||
| Cash Ratio | 18.36 | |||||
| Days Sales Outstanding | 87.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.4 | |||||
| Shareholder Yield % | -37.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2778.89 | |||||
| Net Margin % | -2248.76 | |||||
| FCF Margin % | -2274.89 | |||||
| ROE % | -21.84 | |||||
| ROA % | -20.8 | |||||
| ROIC % | -459.79 | |||||
| 3-Year ROIIC % | -1206.04 | |||||
| ROC (Joel Greenblatt) % | -2801.15 | |||||
| ROCE % | -26.8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 160.27 | |||||
| PB Ratio | 1.52 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | -2.22 | |||||
| EV-to-Forward-EBIT | -1.74 | |||||
| EV-to-EBITDA | -2.25 | |||||
| EV-to-Forward-EBITDA | -1.74 | |||||
| EV-to-Revenue | 61.58 | |||||
| EV-to-Forward-Revenue | 80.05 | |||||
| EV-to-FCF | -2.71 | |||||
| Price-to-GF-Value | 0.53 | |||||
| Price-to-Median-PS-Value | 1.74 | |||||
| Price-to-Net-Current-Asset-Value | 1.62 | |||||
| Price-to-Net-Cash | 1.67 | |||||
| Earnings Yield (Greenblatt) % | -45.05 | |||||
| FCF Yield % | -14.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CLDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celldex Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.02 | ||
| EPS (TTM) ($) | -2.45 | ||
| Beta | 1.23 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.07 | ||
| Volatility % | 38.28 | ||
| 14-Day RSI | 33.94 | ||
| 14-Day ATR ($) | 1.185503 | ||
| 20-Day SMA ($) | 19.8145 | ||
| 12-1 Month Momentum % | -52.04 | ||
| 52-Week Range ($) | 16.4 - 47 | ||
| Shares Outstanding (Mil) | 66.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celldex Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celldex Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celldex Therapeutics Inc Frequently Asked Questions
What is Celldex Therapeutics Inc(CLDX)'s stock price today?
The current price of CLDX is $17.17. The 52 week high of CLDX is $47.00 and 52 week low is $16.40.
When is next earnings date of Celldex Therapeutics Inc(CLDX)?
The next earnings date of Celldex Therapeutics Inc(CLDX) is 2025-05-06 Est..
Does Celldex Therapeutics Inc(CLDX) pay dividends? If so, how much?
Celldex Therapeutics Inc(CLDX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers